In the original version of this article (1), the stated disclosure of Tarek Mekhail is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.
Reference
1.
Riely
GJ
,
Neal
JW
,
Camidge
DR
,
Spira
AI
,
Piotrowska
Z
,
Costa
DB
, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial
. Cancer Discov
2021
;11
:1688
–99
.©2023 American Association for Cancer Research
2023
American Association for Cancer Research
RSS Feeds